The head of England's medicines watchdog has warned against allowing drug prices to climb for years. Jonathan Benger told the Financial Times that yielding to US pressure on pricing would be a 'huge backwards step' for the NHS. His comments come as the government negotiates new pharmaceutical deals.

Benger's stance reflects a core tension in global healthcare: balancing innovation with affordability. The NHS has long relied on cost-effectiveness reviews to keep spending in check. Allowing prices to rise would strain the health budget and could set a worrying precedent for other countries facing similar pressures from the pharmaceutical industry.

This debate is central to upcoming patent negotiations and future drug funding agreements. The outcome will signal how the UK intends to handle pricing pressures post-Brexit. Watch for how this influences the next round of talks between the government and pharmaceutical companies.